FDA Gives Positive Feedback on NRx Pharma's Preservative-Free Ketamine, Targets Summer 2026 Approval
Summary
NRx Pharmaceuticals announced positive feedback from the FDA Office of Generic Drugs regarding its preservative-free ketamine program, including a Discipline Review Letter requesting only minor administrative changes. This significant regulatory progress follows a favorable bioequivalence determination in March and builds on the recent Presidential Executive Order aimed at accelerating psychedelic medical treatments. For a company that recently reported a 'going concern' warning in its 10-K, this positive development is critical. FDA leadership recognized the national priority for ketamine and expressed support for addressing the remaining aspects of the ANDA application within the current review cycle, targeting approval in Summer 2026. This substantially de-risks a key product candidate and provides a clear, near-term catalyst for the stock. Traders will closely monitor further updates on the ANDA process and the anticipated Summer 2026 approval.
At the time of this announcement, NRXP was trading at $2.95 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $97.5M. The 52-week trading range was $1.62 to $3.84. This news item was assessed with positive market sentiment and an importance score of 9 out of 10. Source: GlobeNewswire.